CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
采用已发表对照研究的 CAR-T 细胞疗法治疗 3L+ R/R LBCL 的网状荟萃分析
英文原题：Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
查看英文原题
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们重点指出不同 CAR-T 细胞治疗之间在临床结局上的重要差异。
中文摘要
方法
系统综述纳入比较阿基仑赛（axi-cel）、利基迈仑赛（liso-cel）和替沙仑赛（tisa-cel）临床试验与 SCHOLAR-1 队列中挽救性化疗疗效及安全性结局的研究，患者均既往接受过两线治疗；扩展证据网络还纳入 CAR-T 疗法间的间接比较。研究采用贝叶斯分层模型进行网状荟萃分析。
结果
共识别出三项研究，分别比较 ZUMA-1（axi-cel）、TRANSCEND（liso-cel）和 JULIET（tisa-cel）试验与 SCHOLAR-1 队列中的挽救性化疗。与 tisa-cel 相比，axi-cel（比值比〔OR〕5.63；95% 可信区间〔CrI〕2.66–12.42）和 liso-cel（OR 4.26；95% CrI 2.33–7.93）的总缓解率显著更高，但两者之间没有显著差异。与 liso-cel（风险比〔HR〕0.54；95% CrI 0.37–0.79）和 tisa-cel（HR 0.47；95% CrI 0.26–0.88）相比，axi-cel 的总生存期显著改善。axi-cel 的 3 级神经系统事件发生率高于 tisa-cel 和 liso-cel。
结论
不同 CAR-T 疗法的临床结局存在重要差异。与 tisa-cel 和 liso-cel 相比，axi-cel 可改善总生存期；axi-cel 和 liso-cel 的缓解率均高于 tisa-cel。
展开英文摘要原文
METHODS
Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with 2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies. We conducted network meta-analyzes using Bayesian hierarchical modeling.
RESULTS
Three studies comparing ZUMA-1 (axi-cel), TRANSCEND (liso-cel) and JULIET (tisa-cel) trials to salvage chemotherapy within the SCHOLAR-1 cohort were identified. Axi-cel (odds ratio [OR]:5.63; 95% credible interval [CrI]:2.66-12.42) and liso-cel (OR:4.26; 95%CrI:2.33-7.93) showed a significant increased overall response rate compared to tisa-cel, but not to one-another. Axi-cel demonstrated significant improvements in overall survival relative to liso-cel (hazard ratio [HR]:0.54; 95%CrI:0.37-0.79) and tisa-cel (HR:0.47; 95%CrI:0.26-0.88). Higher rates of grade 3 neurological events were observed with axi-cel than with tisa-cel and liso-cel.
CONCLUSIONS
We highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.
论文信息
- 作者
- Oluwole OO、Neelapu SS、Ray MD、Limbrick-Oldfield EH、Wade SW、Kanters S、Patel AR、Locke FL
- 第一作者单位
- Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.United States
- 通讯作者单位
- H. Lee Moffitt Cancer Center, Tampa, FL, USA.United States
- 文献类型
- 系统综述 · 网状荟萃分析 · 非美国政府资助研究
- 期刊
- Expert review of anticancer therapy2024 Jun
- 原文标识
- PubMed 38646700 · DOI 10.1080/14737140.2024.2343801